There are no interventional studies on the impact of sexual distress (SD) in men with obesity. We investigated the effects of vardenafil (VAR) on SD in middle-aged (mean age 49±8), healthy, obese men in the absence of premature ejaculation, ED or hypogonadism. After a 4-week run-in period, 20 men with high body mass index (BMI ¼ 40±8) and SD at the Sexual Distress Esteem Questionnaire-Male (mean score 65 ± 20 AU) were randomized to receive either VAR 10 mg on demand (N ¼ 10) or matched-placebo (PLB, N ¼ 10). Primary endpoints were variations from baseline in the intravaginal ejaculatory latency time (IELT) measured by the stopwatch technique; secondary endpoints were variations from baseline in Self-Esteem and Relationship (SEAR) and Male Sexual Health Questionnaire-Ejaculatory domain (MSHQ-EjD) scores. VAR significantly improved IELT (Po0.0001), as well as SEAR (Po0.001) and MSHQ-EjD (Po0.005) scores, wheraes no changes were observed after PLB. Interestingly, an inverse relationship between BMI and IELT was found in all the men studied (r 2 ¼ 0.37, Po0.001). SD in healthy obese men seems to be correlated mainly with inadequate ejaculatory control, especially in men with higher BMI. Our preliminary results suggest that treatment with VAR may improve ejaculatory control, thus ameliorating self-esteem and sexual performance in men with obesity.
INTRODUCTION
Male sexual distress (SD) is a relatively recent area of study that is constantly expanding. In 1993, the National Institutes of Health introduced the term ED to replace the term 'impotence,' to indicate the inability to attain and/or maintain a sufficient erection for a satisfactory sexual performance as part of the overall multifaceted investigation of male sexual function. 1 Very recently, the WHO defined sexual health as a 'state of physical, emotional, mental and social well-being, in relation to sexuality; it is not merely the absence of disease, dysfunction or infirmity.' 2 According to the most recent data in literature, SD may be defined as a reduction/absence of 'sexual health,' which results in a feeling of inadequacy, causing a negative impact on sexual responses, not included in the definition of classical ED or in that of 'unconventional requests. ' 3 Inadequacy can originate both from physiological modifications of male sexual functions, or from diseases, that is, dysfunctions, dysfunctional symptoms and dysmorphisms derived from andrological and non-andrological origin, which do not relate to ED (National Institutes of Health Consensus Development Panel definition), but that might also induce ED. Along with requests for situational ED, there are a variety of conditions that do not constitute a classical ED, but may be related with 'inadequate sexual health,' such as the new taxonomy of subclinical ED. 4 These unconventional requests encompass requests for drugs not supported by a disorder or condition, and are rather aimed at enhancing sexual performance, or resulting from misunderstandings and insufficient or inadequate information. The wide variety of SD occurrence is often perceived by the specialist as a prevalent condition, accounting for almost overall 30% requests in the area of sexual medicine. SD is considered potentially curable with different approaches, ranging from an integrated psycho-sexological approach, up to a new use of PDE5-inhibitors, intended as 'tutorial therapy.' This latter implies the administration of PDE5-inhibitors aimed at the resolution of SD and, therefore, must be limited in time, whereas the conventional prescription of PDE5-inhibitors is typically a treatment for an indefinite period.
The aim of the present study was to evaluate the possible association between obesity and SD, and to investigate the efficacy of vardenafil (VAR) 10 mg compared with placebo (PLB) in producing improvement/resolution of SD in obese subjects, according to the subjective assessment of the patient.
PATIENTS AND METHODS
All male obese subjects attending the outpatient department of MetabolicNutritional Rehabilitation of Villa delle Querce (Nemi, Rome) were screened, and gave their informed consent to the study. 10 A total of 20 subjects (mean age 49±8 years) who fulfilled the exclusion/inclusion criteria entered the study. The study period duration was 8 weeks, during which patients underwent a total of three outpatient visits at the time 0, 4 and 8 weeks. Patients underwent a thorough medical history and accurate physical examination (height, weight, vital signs, calculating BMI). The presence of SD was assessed by a specific investigative questionnaire (Sexual Distress Evaluation Questionnaire-Male: SDEQ-M). 11 Each patient was given a diary to record each sexual intercourse attempts (Sexual Encounter Profile) and intravaginal ejaculatory latency time (IELT) by a stopwatch, providing a minimum of four sexual attempts during the study period.
At the end of the run-in period (week 4), the patient's Sexual Encounter Profile diary and IELT were recorded (baseline), and a new Sexual Encounter Profile diary was delivered. The Self-Esteem and Relationship (SEAR) questionnaire was used to evaluate clinically meaningful changes over time as the patient's condition improves or deteriorates during treatment. 12 Four ejaculatory-validated items of the Male Sexual Health Questionnaire-Ejaculatory domain (MSHQ-EjD) 13 were used to evaluate differences in ejaculatory behavior after different treatments. Patients were randomly assigned within each stratum 1:1 by a computerized interactive system to receive PLB (n ¼ 10) or 10 mg VAR (n ¼ 10), and were given eight doses of the study medication (one dose was one tablet; tablets in all groups were identical in appearance as the active principle was encapsulated) for 4 weeks; one dose was to be taken 15 --30 min before anticipated sexual intercourse with empty stomach. At the end-point (week 8), each patient was investigated with SEAR, MSHQ-EjD and SDEQ-M. Each patient was then asked for the occurrence of adverse events or changes in concomitant medications.
With a two-sided alpha value of 5% and power of 90%, a sample size of 10 subjects per arm would be able to detect a 50% increase in the IELT from the baseline. Also, we tested for the differences between treatment groups by using analysis of variance for repeated measures. Multiple regression analysis was carried out for arithmetic mean IELT versus BMI in overall patients. A P-value o0.05 ± s.d. was considered statistically significant. Statistical analysis was carried out using the computer statistical package SPSS/4.0 (SPSS, Chicago, IL, USA) and SAS/6.4 (SAS Institute, Cary, NC, USA).
RESULTS
A total of 50 consecutive obese men were screened. Thirty patients were excluded because of the absence of SD or the presence of at least one exclusion criteria. No significant differences at baseline were found between groups, except for BMI and IELT (Table 1) . No patient underwent significant body weight or pharmacological treatment variations during the study period. Interestingly, significant differences were found for BMI and IELT in respective groups, and this led to an inverse relationship between BMI and IELT (Figure 1 ; Po0.001, r 2 ¼ 0.37). VAR treatment significantly improved IELT (from 326±24 to 449±25 s; Po0.0001; Figure 2 ) compared with PLB. Accordingly, men under VAR significantly improved scores of all sexual questionnaires. Significant differences (Po0.001) from baseline were observed in the overall SEAR scores (Table 2) . Interestingly, a significant improvement was found in the two confidence domain subscales (self-esteem and overall relationship, data not shown). The magnitude of the change was quite high for most aspects in the VAR group (sexual relationship, least square change ¼ 7.5 points; self-esteem, least square change ¼ 8.5), whereas not in the PLB group (sexual relationship, least square change ¼ À22.5 points; self-esteem, least square change ¼ À13.5; Table 2 ).
Interestingly, the validated ejaculatory items (EjD) of MSHQ revealed significant improvements after VAR (Po0.005), whereas the PLB group reported significant worsening (Table 2) .
Finally, three questions of the SDEQ-M questionnaire were selected (Q4, Q5 and Q7), which were highly consistent with the presence of SD at baseline. We arbitrarily assigned to the SDEQ-M questions a score ranging from 0 --10 points and then calculated the differences after each treatment. Regarding Q4, Q5 and Q7, there was a significant improvement in the VAR group (from 8 ± 1.5 to 3.2 ± 3 SD, Po0.005; from 6.6 ± 2.2 to 4.4 ± 1.8 SD, Po0.01; from 7.2 ± 2 to 1.8 ± 2.3 SD Po0.005, Table 2 ). Patients under PLB showed no modification in Q4 (Table 2) , a worsening in Q5 scores and some improvement in Q7 scores, respectively (Table 2) . Notably, there were significant differences in baseline Q4 and Q5 scores between different groups reflecting baseline differences in BMI.
DISCUSSION
To our knowledge, this is the first interventional study investigating SD outcomes in a population of healthy obese men without ED, PE or sexual desire disorders. The importance of the present findings needs to be confirmed by larger studies. We have observed that treatment with VAR improved the duration of erection and the quality of ejaculation, as well as self-esteem and the quality of relationship with the partner. To this purpose, we have used validated instruments, such as the SEAR questionnaire, a valid instrument for detecting psychosocial gain from beneficial interventions, and MSHQ-EjD for the evaluation of three ejaculatory function items (force, volume and frequency of ejaculation). By contrast, PLB treatment led to no improvement in the parameters studied.
It is known that obesity severely impacts on quality of life and, especially, on many aspects of sexual satisfaction, both in male and females. 14 The relationship between BMI and sexual function has, hitherto, been sparsely studied. A recent literature review of obesity and sexual function suggested some evidence for an association between obesity and ED. 15 It is reported that ED may affect obese men, especially both in younger 16 or in those older men with co-morbidities, 17 and that tailored diet is able to restore sexual function when metabolic syndrome is present. 18 Accordingly, the origin of ejaculatory complaints in obese men is poorly investigated. An interesting association between obesity and lifelong PE exists, and some authors reported that patients with lifelong PE were leaner than the healthy control cases, and the prevalence of obesity was lower in the PE group than in the control group. 19 However, this was a retrospective study, in which the authors enrolled moderately overweight men (mean BMI 27.5) and compared them with normal weight controls (mean BMI ¼ 25). These data are in contradiction with those of our study, where we found an inverse relationship between IELT and BMI, thus suggesting that leaner subjects have longer duration of erections in the absence of co-morbidities. Also, PE and ED share a vicious circle where a man trying to control his ejaculation instinctively reduces his level of excitation (which can lead to ED) and a man trying to achieve an erection basically attempts to increase his excitation (which can lead to PE). The linking mechanism may also be the lack of ejaculatory control that generates reactive impotence, because of anxiety arising from poor sexual performance. 20 Noteworthy, we excluded premature ejaculators, as well as men with true ED, but included those men fulfilling the definition of subclinical ED, 4 who can be distressed by their condition leading to SD Thus, we can suggest that a disturbance of the duration of erection may be the pathophysiological basis for the onset of SD in obese men unaware of their sexual disturbance. We are aware that obese men are a very difficult-to-treat population in terms of multidisciplinary approach. In fact, the simultaneous presence of a nutritionist, a psychiatrist and an andrologist, and a progressive and continuous lifestyle change represents the primary goal in these patients. However, the 'tutored' administration of VAR may represent the first step towards the improvement of sexual life and a good motivation to weight reduction. Our patients are still in a multidisciplinary program and they are no longer using VAR.
SD is a widespread disease for which up to 2 years ago, there was neither the definition nor the directions on how to identify it and to treat it. SD is not a disease; nonetheless, this condition induces the affected man to seek help from the sexual medicine specialist. Thus, subjects suffering from SD are not primarily affected by disorders regarding sexual functions, such as ED or PE; 20 their sexual health is impaired due to circumstances that include physiological modifications in erectile functions, as well as disorders, dysfunctions, dysfunctional symptoms and dimorphisms, of both andrological and non-andrological origin, not included in the ED definition. Examples of this latter may include penile dysmorphophobia or inadequate duration of erection associated with severe obesity. In such cases, the subjects, not satisfied with the size of their burred penis, or suffering from poor ejaculatory control despite normal erectile functions, may develop a feeling of sexual inadequacy, possibly leading to erectile difficulties. 3 To our knowledge, this is the first study investigating such aspects in healthy obese male subjects. We found that SD in men with obesity is a common and underestimated condition, affecting 40% of subjects investigated by SDEQ-M questionnaire, in the absence of ED or PE. Also, we found significant differences at baseline in some SD-selected items (Q4 and Q5), reflecting in our opinion the significant differences in BMI between the two groups. Despite this aspect, VAR treatment was able to improve all item scores, which we considered suggestive for the presence of SD in our patients.
We are aware of the apparent limitations of the study that consist mainly in the low number of subjects investigated, and for this reason, the randomization was not successful in matching baseline BMI and IELT. Obviously, this introduced a bias that suggests caution with the interpretation of data. However, the analysis of the statistical power and of the sample size allowed us to demonstrate our initial hypothesis. In this view, we believe that the use SDEQ-M questionnaire suggests its potential use in future diagnostic approach to obese patients, along with SEAR and MSHQ-EjD that give measurement of the results in terms of satisfaction of sexual life with therapy. The present paper is not in the way to make any correlation with endocrine or biochemical obesity-related aspects, as these parameters were not included in the study design, and thus, the population of obese subjects included is not representative of the whole obese people. Hence, the results can be applied only to the obese people with the characteristics indicated. Moreover, we did investigate neither the female partner with specific questionnaires, nor we had information about their BMI.
In conclusion, our preliminary data suggest that VAR may improve the quality of sexual life in obese men complaining SD. We cannot exclude that other confounding factors other than IELT might have impacted on the results of quality of life in our patients. Studies aimed to elucidate other factors influencing sexual performance in obese men are warranted.
